BridgeBio Pharma (BBIO) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 22.6% versus a gain of 9.3%. Over five years, BBIO leads with a +38.6% price change compared with -31.3% for ELAN. BridgeBio Pharma is the larger company by market cap ($13.00 billion vs $11.17 billion), about 1.2 times the size.
On valuation, Elanco Animal Health trades at a lower forward P/E (17.4x vs 2420.8x for BridgeBio Pharma). Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | ELAN |
|---|---|---|
| Share price | $66.50 | $22.36 |
| Market cap | $13.00B | $11.17B |
| 1-day change | -0.69% | -0.53% |
| YTD return | -13.06% | -1.19% |
| 1-year return | +22.65% | +9.34% |
| 5-year return | +38.60% | -31.28% |
| Forward P/E | — | 17.40 |
| EPS (TTM) | $-3.56 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $4.71B |
| Revenue growth (YoY) | +126.26% | +6.22% |
| Net income (latest FY) | $-732.94M | $-232.00M |
| Gross margin | 95.82% | 54.99% |
| Operating margin | -104.25% | — |
| Net margin | -145.98% | -4.92% |
| 52-week high | $93.42 | $27.98 |
| 52-week low | $52.75 | $19.40 |
| Distance from 52-week high | -28.81% | -20.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.98% | +38.64% |
| Average volume | 2.76M | 6.21M |
| Shares outstanding | 195.49M | 499.45M |
| Employees | 999 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed ELAN by 13.3 percentage points over the past year.
- Elanco Animal Health is more profitable, keeping -4.9 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +6.22%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
BBIO vs ELAN FAQ
Which is bigger, BridgeBio Pharma or Elanco Animal Health?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $13.00B compared with $11.17B for Elanco Animal Health (ELAN).
Which stock has performed better over the past year, BBIO or ELAN?
BBIO returned +22.65% over the past 12 months, compared with +9.34% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.